Intocell Co., Ltd. (287840)

Overview

Intocell Co., Ltd. is a pioneering biotechnology enterprise headquartered in Daejeon, South Korea, established in 2015. The company specializes in the advancement of antibody-drug conjugate (ADC) platform technologies, emphasizing innovation in linkers, payloads, and conjugation methods. Its mission is to enhance the efficacy and safety of targeted cancer therapies through cutting-edge solutions that mitigate the shortcomings associated with traditional ADCs, such as solubility limitations and functionalization issues.

Utilizing its proprietary scaffolds, ligands, toxins, and advanced linker chemistries, Intocell has developed unique offerings, including the OHPAS linker and novel benzodiazepine payloads. These innovations support pharmaceutical and biotech firms in creating next-generation precise therapeutics. By contributing to the evolving landscape of oncology drug development, Intocell positions itself as a significant player within the biotechnology sector, dedicated to broader efforts in precision medicine and cancer treatment.

Products and Services

• OHPAS Linker

  This proprietary linker technology is designed to improve the stability and performance of antibody-drug conjugates, facilitating more effective delivery of therapeutics directly to cancer cells.

• Novel Benzodiazepine Payloads

  These uniquely engineered payloads address common limitations of traditional ADC toxins, such as solubility and delivery issues, to enhance the therapeutic index and improve patient outcomes.

• Advanced Linker Chemistries

  Intocell provides a range of innovative chemistries designed for optimal bioconjugation, ensuring that therapeutics maintain functionality throughout their lifecycle, which is critical for effective cancer treatment.

• Custom Connector Solutions

  The company offers tailored solutions for linking antibodies and drug payloads, allowing clients to develop ADCs that are specifically suited to their therapeutic targets and mechanisms of action.

• Consultative Support in ADC Development

  Intocell partners with pharmaceutical and biotech firms, offering expert guidance and support in designing and optimizing ADCs, facilitating a smoother path from development to clinical application.